NEW APPROACH TO MANAGING CHRONIC PAIN NOW AVAILABLE IN CANADA ~ NNUCYNTATM* CR combines two mechanisms of action in a single molecule

~ Toronto, ON (May 16, 2011) Janssen Inc. has announced that NNUCYNTATM CR (tapentadol controlled-release) is now available in Canada for the management of moderate to moderately severe pain.1 This unique treatment option offers sustained pain relief with significantly fewer side effects for the 25 per cent of Canadians who live with chronic pain.2
N

NUCYNTATM CR combines two mechanisms of action in a single molecule: -opioid receptor

agonism and inhibition of norepinephrine reuptake.3 The two mechanisms of action act synergistically to treat different types of pain by optimizing pain relief and minimizing treatment-limiting side effects.4,5,6,9 Clinical trials have demonstrated that in patients with moderate to severe chronic pain,
N N

NUCYNTATM CR resulted in significant pain reduction compared to placebo.7 Furthermore, NUCYNTATM CR demonstrated a marked reduction in gastrointestinal (GI) side effects such as

nausea, vomiting and constipation, and central nervous system (CNS) side effects such as dizziness and somnolence, compared to oxycodone.8 Additionally, the long term safety and efficacy of NNUCYNTATM CR has been shown in two separate studies over a 12-month and two year period of continuous treatment.9, 10 The effects of chronic pain are far-reaching and go beyond just the condition itself. Pain is often undermanaged in part due to medication side effects which impact a persons quality of life and, in some cases, cause patients to discontinue their treatment, says Dr. Kevin Rod, Director, Toronto Poly Clinic pain management centre. Well-tolerated treatment options, such as
N

NUCYNTATM CR, are needed to help patients safely and effectively manage their pain.

According to a recent survey designed to study chronic pain in general, more than 40 per cent of patients who discontinued their chronic pain treatment did so because of side effects.11 The most commonly cited side effects were GI-related, specifically stomach problems (57 per cent) and constipation (38 per cent). Furthermore, 18 per cent of time missed at work due to pain was the result of medication side effects. People who suffer from chronic pain are often on multiple medications, putting them at greater risk for serious side effects that could result from medications interacting in the body, says Dr. Rod. Because of the way NNUCYNTATM CR is metabolized in the body, it is unlikely to cause clinically relevant drug-drug interactions. About NNUCYNTATM CR
N

NUCYNTATM CR is a novel prescription analgesic developed to help manage moderate to NUCYNTATM CR is taken orally approximately every 12 hours.13 NNUCYNTATM CR is

moderately severe pain in adults who require continuous treatment for several days or more.12
N

available for individual dosing in strengths of 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg.14 The most common adverse reactions (reported by 10% in any NNUCYNTATM CR dose group) were nausea, dizziness, constipation, headache and somnolence.15 Patients who have received NNUCYNTATM CR should be closely monitored, especially for signs of respiratory depression, until a stable maintenance dose is reached.16 In general, opioids have been associated with craving, drug-seeking behaviour and tolerance development. NNUCYNTATM CR tablets should not be used in opioid-dependent patients.17 Experience with NNUCYNTATM CR overdose is limited. Current data suggest that patients without a history of substance abuse are unlikely to become addicted to opioids over long-term treatment of chronic pain.18

Please see NNUCYNTATM CR product monograph for complete prescribing information including contraindications. About Janssen Inc. As a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Inc. is dedicated to addressing and solving the most important unmet medical needs in pain management, psychiatry, oncology, psoriasis, virology, anemia, attention deficit hyperactivity disorder, dementia, gastroenterology and womens health. Driven by our commitment to the passionate pursuit of science for the benefit of patients, we work together to bring innovative ideas, products and services to patients around the world. - 30 * All trademark rights used under license.

For more information please contact: Sarah Bannoff Edelman sarah.bannoff@edelman.com (416) 849-8925 Jennifer McCormack Janssen Inc.
jmccorm3@ITS.JNJ.com

(416) 449-9444

References:
1 2 N

7 8 9

10

11

12 13 14 15 16 17 18

NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 3. Boulanger et al. Chronic pain in Canada: Have we improved our management of chronic noncancer pain? Pain Research & Management. Vol 12(1), Spr 2007, pp. 39-47. Tzschentke et al. Tapentadol hydrochloride: A next-generation, centrally-acting analgesic with two mechanisms of action in a single molecule. Drugs of Today. 2009. Vol 45 (7), pp. 483-496. Lange et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010. Vol 27 (6), pp. 381-399. Afilalo et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee. Clin Drug Investig. 2010. Vol 30 (8), pp. 489-505. Buynak et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, -double blind, placebo-and active-controlled Phase 3 study. Expert Opin. Pharmacophr. 2010. Vol 11 (11), pp. 1787-1804. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 21-24. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 11-12. Wild et al. Long term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Practice. Vol 10 (5), 2010. pp. 425. Etropolski et al. Efficacy and function following up to two years tapentadol extended release treatment in patients with chronic pain. Poster Presentation at the 64 th Annual Meeting of the Postgraduate Assembly in Anesthesiology (PGA). December 2010, New York. The chronic pain survey was conducted from December 5 to 13, 2010 by Ipsos Reid through an online survey of a randomly selected, representative sample of 1,053 adult Canadians who suffer from chronic, non-cancer pain. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 3. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 15. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 20. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 10. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 4. N NUCYNTATM CR Product Monograph, Janssen Inc., 2010. Page 5. Substance Abuse: A Comprehensive Textbook. Joyce H. Lowinson, Robert B. Millman, John G. Langrod, Pedro Ruiz. 4th Edition. Lippincott Williams & Wilkins. October 2004. p.892.